meropenemvaborbactam
Meropenem/vaborbactam is a fixed‑dose antibiotic combination consisting of the carbapenem meropenem and the novel beta‑lactamase inhibitor vaborbactam. It is used for adults with complicated urinary tract infections, including pyelonephritis, and for complicated intra‑abdominal infections, particularly when bacteria may produce carbapenemase enzymes such as KPC.
Mechanism of action and rationale: Meropenem interferes with bacterial cell wall synthesis by inhibiting penicillin‑binding proteins.
Antimicrobial spectrum: The regimen is active primarily against Gram‑negative Enterobacterales, especially KPC‑producing strains. Its activity against
Administration and dosing: Meropenem/vaborbactam is given intravenously, typically as a total daily dose of 4 g
Safety and monitoring: Common adverse events include diarrhea, nausea, headache, and injection‑site reactions. Risks include Clostridioides
Regulatory status and clinical use: It has been approved in multiple jurisdictions for complicated urinary tract